Please use this identifier to cite or link to this item: http://nopr.niscair.res.in/handle/123456789/54176
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSingh, Amit-
dc.contributor.authorGupta, Paramita Das-
dc.date.accessioned2020-03-16T06:54:06Z-
dc.date.available2020-03-16T06:54:06Z-
dc.date.issued2019-05-
dc.identifier.issn0975-1076 (Online); 0971-7544 (Print)-
dc.identifier.urihttp://nopr.niscair.res.in/handle/123456789/54176-
dc.description69-88en_US
dc.description.abstractData-exclusivity is one of the most controversial issues in the current discussion on pharmaceutical intellectual property policy-making globally. It is aimed at protecting and safeguarding pharmaceutical test data submitted by pharmaceutical companies to drug regulatory authorities (DRA) for the purpose of obtaining marketing approval for new drugs. Most countries require the submission of test data relating to the efficacy and safety of pharmaceuticals and agro-chemicals as a condition for grant of marketing approval. Since the marketing approval process is laborious and expensive, the originators of such regulatory data demand protection for their investments through exclusivity periods, separate from any patent protection for the active ingredient. On the other hand, generic manufacturers advocate minimal protection for such data as they would be able to obtain speedier marketing approvals. Data-exclusivity thus, prevents during a set period of time, a second pharmaceutical applicant from obtaining a marketing authorization for its drug through a facilitated procedure; this procedure entails reliance by the second applicant on preclinical and clinical data generated by a pioneer company that prepared that data to support its own new drug application. The underlying logic of data-exclusivity suggests that it is an expression of trade-secrets, and that as such, data-exclusivity should be independent of patents. Compared with patents, the market power of data-exclusivity is, in theory, less restrictive, mainly because it does not legally prevent other companies from generating their own registration data. However, in practice, the vast financial resources and extended time required for gathering and generating pharmaceutical registration data for a new drug create a market barrier that is too high for generic based companies.en_US
dc.language.isoen_USen_US
dc.publisherNISCAIR-CSIR, Indiaen_US
dc.rights CC Attribution-Noncommercial-No Derivative Works 2.5 Indiaen_US
dc.sourceJIPR Vol.24(3-4) [May-July 2019]en_US
dc.subjectTRIPSen_US
dc.subjectDrugs and Cosmetics Act (DCA), 1940en_US
dc.subjectTrans-Pacific Partnership (TPP) Agreementen_US
dc.subjectEuropean Union Data-exclusivity Union, 2005en_US
dc.subjectData-exclusivityen_US
dc.subjectDrug regulatory authorityen_US
dc.subjectPharmaceutical patentsen_US
dc.subjectTest data protectionen_US
dc.subjectResearch and developmenten_US
dc.subjectNew chemical entitiesen_US
dc.titlePharmaceutical Test Data Protection and Demands for Data-Exclusivity: Issues and Concerns of Developing Countries and India’s Positionen_US
dc.typeArticleen_US
Appears in Collections:JIPR Vol.24(3-4) [May-July 2019]

Files in This Item:
File Description SizeFormat 
JIPR 24(3-4) 69-88.pdf116.88 kBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.